share_log

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

百时美施贵宣布其COBENFY第3期研究的上市数据显示,精神分裂症症状持续改善。
Benzinga ·  16:19

Bristol Myers Squibb Announced Topline Data From Its Phase 3 Study Of COBENFY That Showed Continuing Improvement In Symptoms Of Schizophrenia

百时美施贵宣布其COBENFY第3期研究的上市数据显示,精神分裂症症状持续改善。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发